15 Prostate Cancer Clinical Trials in Aurora, IL (2026)

Q: How do I join a clinical trial in Aurora?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you.

Recruiting Prostate Cancer Studies in Aurora

NCT06925737Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-...

Aurora, IL1,440 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06136650Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Me...

Aurora, IL1,314 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06136624Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) ...

Aurora, IL1,310 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06764485Recruiting

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer....

Aurora, IL960 participantsCelgene

View Study Details

NCT02960022Recruiting

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutam...

Aurora, IL900 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07365995Recruiting

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (g...

Aurora, IL736 participantsBioNTech SE

View Study Details

NCT05803941Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 17...

Aurora, IL700 participantsNovartis Pharmaceuticals

View Study Details

NCT07611110Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in ...

Aurora, IL670 participantsAstraZeneca

View Study Details

NCT07164443Recruiting

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive...

Aurora, IL663 participantsJanssen Research & Development, LLC

View Study Details

NCT04221542Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate pr...

Aurora, IL479 participantsAmgen

View Study Details

NCT07285694Recruiting

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC)....

Aurora, IL190 participantsArsenal Biosciences, Inc.

View Study Details

NCT06785636Recruiting

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration...

Aurora, IL120 participantsPathos AI, Inc.

View Study Details

NCT04038502Recruiting

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant p...

Aurora, IL100 participantsVA Office of Research and Development

View Study Details

NCT05515978Recruiting

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation...

Aurora, IL100 participantsUniversity of Colorado, Denver

View Study Details

NCT05011383Recruiting

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermitt...

Aurora, IL51 participantsVA Office of Research and Development

View Study Details

About Prostate Cancer Clinical Trials in Aurora

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 15 prostate cancer clinical trials recruiting participants in Aurora, IL. These studies are seeking a combined 9,733 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Celgene, Astellas Pharma Global Development, Inc. and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Aurora — FAQ

Are there prostate cancer clinical trials in Aurora?

Yes, there are 15 prostate cancer clinical trials currently recruiting in Aurora, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 15 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated July 13, 2026 from ClinicalTrials.gov